ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Attovia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$13.89+0.16 (+1.17%)
Close on Oct 19, 2026
- Market cap
- $58.86M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Attovia Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
13 buys · 92 sales
Net bought $63.93M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Frazier Life Sciences XI, L.P. | 6,154,213 | 13.50% | 13D (active) | Aug 6, 2026 |
| David Kroin | 3,207,138 | 7.45% | 13G (passive) | Aug 5, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Attovia Therapeutics, Inc. | President and CEO, Director | 449,371 | 0.98% | Aug 6, 2026 |
| Hubert Chen | Chief Medical Officer | 2,960 | 0.01% | Aug 6, 2026 |
| Zaneta Odrowaz | Chief Business Officer | 103,269 | 0.23% | Aug 6, 2026 |
| Petter Veiby | Chief Scientific Officer | 104,951 | 0.23% | Aug 6, 2026 |
| Colin Walsh | Director | 2,520,632 | 5.52% | Aug 28, 2026 |
| Mitchell Gold | Director | – | – | Aug 6, 2026 |
| Angie You | Director | 52,852 | 0.12% | Aug 6, 2026 |
| John W. Smither | Director | – | – | Aug 4, 2026 |
| James N. Topper | Director | – | – | Aug 4, 2026 |
| Aaron Royston | Director | – | – | Aug 4, 2026 |
| Sachs Group Inc Goldman | – | – | – | Aug 28, 2026 |
| Wsls Offshore Investments, Slp | – | – | – | Aug 28, 2026 |
| Broad Street Principal Investments, L.L.C. | – | – | – | Aug 28, 2026 |
| Goldman Sachs Asset Management, L.P. | – | 3,020,632 | 6.62% | Aug 28, 2026 |
| Wsls Emp Onshore Investments, L.P. | – | – | – | Aug 28, 2026 |
| West Street Life Sciences I, L.P. | – | – | – | Aug 28, 2026 |
| Sachs & Co. Llc Goldman | – | 2,042,134 | 4.47% | Aug 28, 2026 |
| Wsls Emp Offshore Investments, L.P. | – | – | – | Aug 28, 2026 |
| venBio Global Strategic Fund IV, L.P. | 10% owner | 3,799,015 | 8.32% | Aug 10, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 10% owner | 1,957,138 | 4.29% | Aug 10, 2026 |
| David Kroin | 10% owner | – | – | Aug 10, 2026 |
| Deep Track Capital, LP | 10% owner | – | – | Aug 10, 2026 |
| Redmile Biopharma Investments III, L.P. | 10% owner | – | – | Aug 7, 2026 |
| Sanofi | 10% owner | 1,082,855 | 2.37% | Aug 7, 2026 |
| Jeremy Green | 10% owner | 2,948,562 | 6.46% | Aug 7, 2026 |
| Redmile Group, LLC | 10% owner | – | – | Aug 7, 2026 |
| Fhmls Xi, L.P. | 10% owner | 1,824,541 | 4.00% | Aug 6, 2026 |
| Fhmls Xi, L.L.C. | 10% owner | – | – | Aug 6, 2026 |
| Frazier Life Sciences XI, L.P. | 10% owner | – | – | Aug 6, 2026 |
| Alamar HoldCo, LLC | 10% owner | 3,229,278 | 7.07% | Aug 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Colin Walsh Director | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Colin Walsh Director | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| Colin Walsh Director | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Goldman Sachs Asset Management, L.P. – | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Goldman Sachs Asset Management, L.P. – | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Goldman Sachs Asset Management, L.P. – | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| Sachs & Co. Llc Goldman – | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| Sachs & Co. Llc Goldman – | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Sachs & Co. Llc Goldman – | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Colin Walsh Director | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Colin Walsh Director | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Colin Walsh Director | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Conversion | +665,147 | – | – | 3,799,015 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Conversion | +2,311,870 | – | – | 2,311,870 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Conversion | +821,998 | – | – | 3,133,868 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Buy | +382,352 | $17.00 | $6.50M | 4,181,367 |
| Deep Track Biotechnology Master Fund, Ltd. 10% owner | Aug 6, 2026 | Conversion | +1,957,138 | – | – | 1,957,138 |
| Sanofi 10% owner | Aug 6, 2026 | Buy | +300,000 | $17.00 | $5.10M | 1,082,855 |
| Sanofi 10% owner | Aug 6, 2026 | Conversion | +782,855 | – | – | 782,855 |
| Jeremy Green 10% owner | Aug 6, 2026 | Buy | +400,000 | $17.00 | $6.80M | 1,182,854 |
| Jeremy Green 10% owner | Aug 6, 2026 | Conversion | +782,854 | – | – | 782,854 |
| Jeremy Green 10% owner | Aug 6, 2026 | Buy | +200,000 | $17.00 | $3.40M | 982,854 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +1,749,192 | – | – | 1,824,541 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +1,590,175 | – | – | 3,414,716 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +1,189,940 | – | – | 4,604,656 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +961,322 | – | – | 5,565,978 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Buy | +588,235 | $17.00 | $10.00M | 6,154,213 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −76,418 | $21.04 | $1.61M | 0 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −6,763 | $21.61 | $146.15K | 55,611 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −100 | $21.99 | $2.20K | 62,374 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,163 | $22.19 | $25.81K | 62,474 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −700 | $22.07 | $15.45K | 63,637 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −200 | $22.05 | $4.41K | 64,337 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −443 | $21.78 | $9.65K | 64,537 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −300 | $20.84 | $6.25K | 64,980 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,040 | $22.05 | $22.93K | 65,280 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,180 | $21.84 | $25.77K | 66,320 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −400 | $22.02 | $8.81K | 67,500 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −6,970 | $22.03 | $153.55K | 67,900 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −672 | $22.02 | $14.80K | 74,870 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −753 | $21.97 | $16.54K | 75,542 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −100 | $22.11 | $2.21K | 76,295 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −480 | $21.55 | $10.34K | 76,395 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −3,402 | $22.02 | $74.91K | 77,075 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,556 | $22.06 | $34.33K | 80,477 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −200 | $22.05 | $4.41K | 82,033 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,332 | $22.03 | $29.34K | 82,233 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −447 | $21.87 | $9.78K | 83,565 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −988 | $22.03 | $21.77K | 84,012 |
| Colin Walsh Director | Aug 5, 2026 | Buy | +85,000 | $21.00 | $1.79M | 85,000 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −200 | $22.10 | $4.42K | 76,875 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −100 | $22.11 | $2.21K | 76,295 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −480 | $21.55 | $10.34K | 76,395 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −200 | $22.10 | $4.42K | 76,875 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −3,402 | $22.02 | $74.91K | 77,075 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −1,556 | $22.06 | $34.33K | 80,477 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −200 | $22.05 | $4.41K | 82,033 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −1,332 | $22.03 | $29.34K | 82,233 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −447 | $21.87 | $9.78K | 83,565 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −988 | $22.03 | $21.77K | 84,012 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.